Descovy
HIV Prevention: Considerations for Adolescents and Young Adults
During the adolescent and young adult years, people are faced with significant physical and developmental changes ...
APRIL 30, 2025
USPSTF Gives ‘A’ Rating to All 3 Approved PrEP Medications, but Access Challenges Remain
In addition to Truvada, the new recommendations also include the daily oral drug Descovy and the long-acting ...
SEPTEMBER 1, 2023
High Rates of PrEP Adherence and Persistence for F/TAF Patients
Patients who are naive to HIV PrEP and prescribed Descovy (Gilead) have a greater number of prescription ...
DECEMBER 19, 2022
FDA Grants New Indication for Descovy for PrEP
Descovy for PrEP is indicated to reduce the risk for sexually acquired HIV-1 infection in adults and adolescents ...
OCTOBER 3, 2019
Good Virologic Response Seen for Bictegravir in HIV
News from CROI 2017: Gilead's novel, investigational drug appears to be promising in rapidly suppressing HIV.
FEBRUARY 15, 2017
